SMS alerts can make the difference between a profitable trade and a missed opportunity.
 Text “MOMO” to 555888 to receive our instant, reliable and free SMS alerts.

Traders and Investors,

That's how much International Endeavors Corporation (IDVV) skyrocketed in just two days last month. In fact, it was more like 173%, and on very little volume no less.

IDVV doesn't need much trading volume to register explosive gains, the level 2 is extremely thin, the market cap so small and the float is very tight.

It recently traded at over $0.80. Now having pulled back to $0.38 right above technical support, IDVV is once again on trader's radars for a bounce higher.

IDVV, like many of the big winners in the market of late, operates in the super hot cannabis space.

I'm not going to bore you with the growth statistics of the medical marijuana industry - these have been well documented many times in this newsletter. Suffice to say the growth potential is enormous.

Just know that IDVV has a point of difference to many others operating in the industry.

Specifically, IDVV is  focused on biomedical uses of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the Company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases.


In the past month the Company has announced some rather big (and exciting) news... the market obviously liked what they had to say because their share price skyrocketed on news that IDVV signed an MOU with Kubby Cryogenics Inc.

Under the terms of this agreement Steve Kubby will immediately become CEO of International Endeavor Corporation.

Steven Wynn "Steve" Kubby, played a key role in the passage of California Proposition 215, a ballot initiative passed in 1996 to legalize medical marijuana. He is a well-known cancer patient of 36 years, who benefits his recovery through the use of non-psychoactive Cryogenics, a raw cannabis extract.

Steve Kubby was formally Chairman and CEO of Cannabis Sativa Inc., traded under the symbol CBDS, and has authored 2 books on drug policy reform. Mr. Kubby's distinguished political career includes runs for Governor of California in 1998, and the 2008 Presidential primary race under the libertarian ticket.

Kubby Cryogenics will look to patent medical grade cannabis strains that are genetically profiled to treating specific diseases.

According to the press release, the potential uses for Cryogenics reaches far and wide, including Cancer, Fibromyalgia, Arthritis, High Blood Pressure, Epilepsy, Brain Injury, Stroke, Inflammation, and PTSD.

The company will be acquiring licensing rights to patent new delivery systems in the future. Further, the company will continue with product development in their own proprietary Cryogenics line, which captures the highest medical value of any product known on the market today.

To accomplish these goals, Kubby Cryogenics has assembled a team of top Scientists and Geneticists to research and develop the strains for these Cryogenic Extract products.

Steve Kubby, commented, "We are very excited to partner with IEC, and anticipate bringing a new class of medicine to the market through our pure line of medical grade cannabis products featuring our patent pending Cryogenic process. We will create a dispensary system for legal medical cannabis states standardizing the patient centered, consultation approach while presenting an enticing line of Adult Use products featuring a patent pending menu of powerful strains and pure, all natural, solvent-less concentrate products."

And in recent weeks, the Company updated the market on KUBBY Cryogenics, Inc.

Kubby Cryogenics manufacturing division produces a unique biomedicine from the raw cannabis plant. This new class of medicine, the Kubby Cryogenics method, is the company’s own proprietary method capturing the vitality of the raw plant in its extraction process. This small batch, apothecary approach captures the live resins that have medical benefits for a number of ailments, including: cancer, inflammatory disease, epilepsy, brain injury, autism, Alzheimer’s, and more.

Currently research being done focuses on the medical value in specific strains that may be used in the company’s proprietary Cryogenic process, a broad-spectrum therapy. Kubby Cryogenics is working with genetic partners to secure several medicinal strains to patent for this use. Most people of all ages can potentially use Kubby Cryogenics because it’s naturally a non-psychoactive product.

You can read in full at https://finance.yahoo.com/news/iec-issues-corporate-kubby-cryogenics-130000898.html

As you can see, IDVV is all about potential. The chart is screaming for another breakout, and as I mentioned earlier, it doesn't take much to get it going. 

Some 173% gains in two days last month, I'd be a happy camper if it can repeat this time around.

Be careful though, the level 2 is so thin and market cap so small that IDVV could run away without you if your not fast enough.

Do your DD and be ready to trade at market open tomorrow.
 

 

 

Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity.